MAHOGANYNCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 65 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Study sites revised (264)
- Notable Eligibility criteria expanded, about 11 words
- Secondary endpoints: details revised at 3 of 11 entries
- Study sites revised (264)
- Minor Study sites: 266 to 264v63
- Minor Study sites: 268 to 266v62
- Minor Study sites: 270 to 268v61
- Minor Trial sites expanded: 257 → 270 locationsv60
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Trial sites reduced: 277 → 257 locations
- Enrollment target: estimated 780 to confirmed 799
- Minor Study sites revised (277)v58
- Notable Sponsor changed: BeiGene to BeOne Medicines
- Site details revised at 8 of 277 sites
- Minor Site details revised at 2 of 277 sitesv56
- Minor Study sites revised (277)v55
- Minor Site details revised at 1 of 277 sitesv54
- Minor Study sites revised (277)v53
- Minor Study sites: 258 to 277v52
- Minor Study sites: 259 to 258v51
- Minor Site details revised at 2 of 259 sitesv50
- Minor Study sites: 256 to 259v49
- Minor Study sites: 259 to 256v48
- Minor Study sites: 265 to 259v47
- Minor Site details revised at 27 of 265 sitesv46
- Minor Study sites: 289 to 265v45
- Minor Site details revised at 10 of 289 sitesv44
- Minor Study sites: 291 to 289v43
- Minor Study sites: 294 to 291v42
- Minor Enrollment target: 750 to 780v41
- Minor Study sites: 287 to 294v40
- Minor Study sites: 290 to 287v39
- Minor Study sites: 298 to 290v38
- Minor Study sites: 300 to 298v37
- Minor Study sites: 295 to 300v36
- Minor Study sites: 294 to 295v35
- Minor Site details revised at 1 of 294 sitesv34
- Minor Study sites: 175 to 294v33
- Minor Study sites: 237 to 175v32
- Minor Study sites: 253 to 237v31
- Minor Study sites: 244 to 253v30
- Notable Eligibility criteria expanded, about 22 words
- Study sites: 236 to 244
- Minor Study sites: 228 to 236v28
- Minor Study sites: 224 to 228v27
- Minor Study sites: 216 to 224v26
- Minor Study sites: 203 to 216v25
- Minor Study sites: 181 to 203v24
- Minor Study sites: 171 to 181v23
- Minor Study sites: 154 to 171v22
- Minor Study sites: 137 to 154
- Primary completion date: Aug 2028 to Jul 2028
- Study completion date: Jun 2029 to Jun 2030
- Minor Study sites: 115 to 137v20
- Minor Study sites: 87 to 115v19
- Minor Study sites: 71 to 87v18
- Minor Study sites: 54 to 71v17
- Minor Study sites: 43 to 54v16
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
Participants will receive lenalidomide and rituximab.
Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
Participants will receive lenalidomide and rituximab.
Drugs: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab
Sites
264 sites in 28 countries
United States 50, China 38, Brazil 22, Australia 17, Spain 16, Japan 13, South Korea 13, Canada 10, Italy 10, Poland 9, United Kingdom 9, France 8, Israel 7, Austria 5, Turkey (Türkiye) 5, Belgium 4, Romania 4, Greece 3, Portugal 3, Switzerland 3, Argentina 2, Bulgaria 2, Czechia 2, Germany 2, Ireland 2, Puerto Rico 2, South Africa 2, Georgia 1